Benzinga

Benzinga Japan

Benzinga

Benzinga Japan

Benzinga

Benzinga Japan
金曜日, 9 04

Protagonist Therapeutics Inc

PTGXNASDAQ
Trade with Public
Trade with Public
$148.80
2.721.86%
近くで: Sep 2, 5:00 PM EST
$148.80
2.721.86%
プレマーケット: 7:00 AM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Protagonist Therapeutics Financials

Protagonist Therapeutics (PTGX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Protagonist Therapeutics Q2 EPS $2.29 Beats $1.66 Estimate, Sales $213.475M Beat $203.764M Estimate

Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $2.29 per share which beat the analyst consensus estimate of $1.66 by 37.95 percent. This is a 516.36 percent increase over losses of $(0.55) per
Benzinga Newsdesk

PRO
Protagonist Therapeutics Q1 EPS $0.05 Beats $(0.42) Estimate, Sales $56.368M Beat $16.273M Estimate

Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.42) by 111.9 percent. This is a 126.32 percent increase over losses of $(0.19) per
Benzinga Newsdesk

Protagonist Therapeutics Q4 Earnings Summary & Key Takeaways

Benzinga Insights

PRO
Protagonist Therapeutics Q4 EPS $(0.69) Misses $(0.24) Estimate, Sales $7.437M Miss $8.926M Estimate

Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.24) by 191.14 percent. This is a 134.85 percent decrease over earnings of $1.98 per
Benzinga Newsdesk

PRO
Protagonist Therapeutics Q3 EPS $(0.62) Beats $(0.63) Estimate, Sales $4.712M Beat $3.636M Estimate

Benzinga Newsdesk

Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook

Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthopedics business, DePuy Synthes.
Vandana Singh

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

Benzinga

Benzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved